Literature DB >> 24751628

The developing intestinal microbiome: probiotics and prebiotics.

Josef Neu1.   

Abstract

The microbes in the human intestinal tract interact with the host to form a 'superorganism'. The functional aspects of the host microbe interactions are being increasingly scrutinized and it is becoming evident that this interaction in early life is critical for development of the immune system and metabolic function and aberrations may result in life-long health consequences. Evidence is suggesting that such interactions occur even before birth, where the microbes may be either beneficial or harmful, and possibly even triggering preterm birth. Mode of delivery, use of antibiotics, and other perturbations may have life-long consequences in terms of health and disease. Manipulating the microbiota by use of pro- and prebiotics may offer a means for maintenance of 'healthy' host microbe interactions, but over-exuberance in their use also has the potential to cause harm. Considerable controversy exists concerning the routine use of probiotics in the prevention of necrotizing enterocolitis. This chapter will provide a brief overview of the developing intestinal microbiome and discuss the use of pro- and prebiotics in preterm infants.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24751628     DOI: 10.1159/000358465

Source DB:  PubMed          Journal:  World Rev Nutr Diet        ISSN: 0084-2230            Impact factor:   0.575


  3 in total

Review 1.  Emerging Technologies for Gut Microbiome Research.

Authors:  Jason W Arnold; Jeffrey Roach; M Andrea Azcarate-Peril
Journal:  Trends Microbiol       Date:  2016-07-15       Impact factor: 17.079

Review 2.  The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood.

Authors:  John Slattery; Derrick F MacFabe; Richard E Frye
Journal:  Clin Med Insights Pediatr       Date:  2016-10-09

3.  Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial.

Authors:  Yana Emmy Hoy-Schulz; Kaniz Jannat; Thomas Roberts; Saira Husain Zaidi; Leanne Unicomb; Stephen Luby; Julie Parsonnet
Journal:  BMC Complement Altern Med       Date:  2016-02-02       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.